Patents by Inventor Stuart Emanuel

Stuart Emanuel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20230287034
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J.F. Thuring
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20230146410
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 11, 2023
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Cyclic Dinucleotides As Sting Agonists
    Publication number: 20230144627
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, B1, R2A, and R2B are defined herein.
    Type: Application
    Filed: October 17, 2022
    Publication date: May 11, 2023
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Cyclic dinucleotides as sting agonists
    Patent number: 11597746
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 7, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J. F. Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11492367
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 8, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11472830
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210277046
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 9, 2021
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J.F. Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11021511
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II) wherein R1H, R1K, R1J, and R2L are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan
  • Bispecific EGFR/IGFIR binding molecules
    Patent number: 10954286
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20210040181
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 11, 2021
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210009630
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2, X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 14, 2021
    Inventors: Leonid BEIGELMAN, Gilles BIGNAN, Peter J. CONNOLLY, James Patrick EDWARDS, Stuart EMANUEL, Sylvia LAQUERRE, Mark RICHTER, Wim Gert Griet SCHEPENS, Santhosh Kumar THATIKONDA, Johannes Wilhelmus John Fitzgerald THURING, Marcel VIELLEVOYE, Guangyi WANG, Minghong ZHONG
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 10781247
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 22, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20190375782
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 12, 2019
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20190375781
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II) wherein R1H, R1K, R1J, and R2L are defined herein.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 12, 2019
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan
  • BISPECIFIC EGFR/IGFIR BINDING MOLECULES
    Publication number: 20190153069
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Application
    Filed: November 30, 2018
    Publication date: May 23, 2019
    Inventors: Stuart EMANUEL, Linda ENGLE, Ray CAMPHAUSEN, Martin C. WRIGHT, Ginger Chao RAKESTRAW, Marco GOTTARDIS, Joan CARBONI
  • Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
    Patent number: 10183987
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 22, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
    Publication number: 20180244755
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 30, 2018
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20180162899
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Targeted therapeutics based on engineered proteins that bind EGFR
    Patent number: 9920108
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 20, 2018
    Assignee: BRISTOl-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • BISPECIFIC EGFR/IGFIR BINDING MOLECULES
    Publication number: 20180037631
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Application
    Filed: August 23, 2017
    Publication date: February 8, 2018
    Inventors: Stuart EMANUEL, Linda ENGLE, Ray CAMPHAUSEN, Martin C. WRIGHT, Ginger Chao RAKESTRAW, Marco GOTTARDIS, Joan CARBONI